Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC004 for Pain in Bone Metastases
NCT07731685Phase 1Not yet recruiting
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eratrectinib in bone metastases (3 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoint: Numeric Rating Scale at 4 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
eratrectinib
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT07731685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07731685.